[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.129.152. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Health Agencies Update
November 23/30, 2011

Controversial Chelator Approved

JAMA. 2011;306(20):2207. doi:10.1001/jama.2011.1699

In October, the US Food and Drug Administration (FDA) approved deferiprone, a drug that helps remove heavy metals from the body, for the treatment of iron overload in patients with thalassemia. The drug was approved despite objections from critics, who say the drug's maker has failed to provide adequate data supporting the medication's safety and efficacy.

Patients with thalassemia, a rare disorder that causes anemia, develop iron overload after multiple blood transfusions. Iron overload may increase the risk of liver disease, diabetes, arthritis, heart problems, and death. Deferiprone was approved for patients who have not responded to treatment with other chelation drugs.

First Page Preview View Large
First page PDF preview
First page PDF preview
×